Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
BACKGROUND:Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of the novel H1/IC31 vaccine, a fusion protein of A...
Main Authors: | Klaus Reither, Lynn Katsoulis, Trevor Beattie, Nicolene Gardiner, Nicole Lenz, Khadija Said, Elirehema Mfinanga, Christian Pohl, Katherine L Fielding, Hannah Jeffery, Benjamin M Kagina, Elisabeth J Hughes, Thomas J Scriba, Willem A Hanekom, Søren T Hoff, Peter Bang, Ingrid Kromann, Claudia Daubenberger, Peter Andersen, Gavin J Churchyard |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4260867?pdf=render |
Similar Items
-
Pulmonary aspergilloma: a treatment challenge in sub-Saharan Africa.
by: Christian Pohl, et al.
Published: (2013-01-01) -
The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period
by: Hartmut B. Krentz, et al.
Published: (2012-01-01) -
Aportación al estudio comparativo de resistencia a compresión entre cementos P-350 y PA-350
by: J. Enrique Morales Jiménez
Published: (1981-03-01) -
The Goths and the Balkans A.D. 350-500
by: Heather, P. J.
Published: (1986) -
Chronic airflow obstruction in Tanzania – a cross-sectional study
by: Thomas Zoller, et al.
Published: (2018-01-01)